# Cellbyte **Source:** https://geo.sig.ai/brands/cellbyte **Vertical:** Healthcare **Subcategory:** General **Tier:** Emerging **Website:** cellbyte.com **Last Updated:** 2026-04-14 ## Summary AI pharma drug launch platform compressing market access research from months to minutes; six-figure ARR within weeks of launch with Bayer as client across 12 markets. ## Company Overview Cellbyte is an AI-powered pharmaceutical drug launch platform that accelerates global drug launches by providing real-time pricing and market access intelligence — compressing processes that traditionally take months or years (reference pricing analysis, health technology assessment research, payer landscape mapping) into minutes using AI-driven data aggregation and analysis. Founded in 2024 and a Y Combinator graduate, Cellbyte raised $2.75 million in seed funding led by Frontline Ventures and Y Combinator, achieving six-figure ARR within weeks of launch.\n\nCellbyte's platform aggregates regulatory approval data, drug pricing reference lists, payer coverage policies, and health technology assessment outcomes across multiple countries to help pharmaceutical market access teams make faster, better-informed launch sequence decisions. Global drug launches require navigating distinct pricing and reimbursement systems in each country — reference pricing (where one country's price affects another's) makes launch sequencing strategically critical and data-intensive. Cellbyte automates the research that market access consultants previously performed manually.\n\nIn 2025, Cellbyte secured major clients including Bayer across 12 live markets — demonstrating enterprise adoption velocity unusual for a seed-stage company. The pharmaceutical market access software market includes specialized players like IQVIA (market data), ZS Associates (consulting), and early-stage AI entrants. The total addressable market is substantial given the global pharmaceutical market's hundreds of billions in annual drug launches. Cellbyte's 2025-2026 strategy focuses on expanding the breadth of markets covered (targeting all major pharma markets globally), deepening AI capabilities for predictive pricing modeling, and growing its pharmaceutical client base beyond the initial anchor customers. ## Frequently Asked Questions ### What is Cellbyte? Cellbyte is an AI-powered pharmaceutical drug launch platform that helps pharma companies launch new drugs worldwide through pricing and market access intelligence. The company provides AI agents that bring clinical, pricing, HTA, regulatory, and internal company data into a unified real-time analytical environment. ### What products and services does Cellbyte offer? Cellbyte offers an AI pharma launch platform that provides pricing and market access intelligence for pharmaceutical companies. The platform delivers real-time analytics by consolidating clinical, pricing, health technology assessment, regulatory, and internal company data into one unified environment. ### Who are Cellbyte's target customers? Cellbyte serves pharmaceutical companies launching new drugs globally. Major clients include Bayer, and the company currently operates live in 12 key markets with weekly expansion. ### When was Cellbyte founded? Cellbyte was founded in 2024 by Daniel Moreira, Felix Steinbrenner, and Samuel Moreira. The company participated in Y Combinator's W22 batch. ### Where is Cellbyte located? Cellbyte is based in the United States. The company currently operates live in 12 key markets worldwide with weekly expansion. ### Has Cellbyte raised any funding? Cellbyte raised $2.75M in seed funding in November 2024 led by Frontline Ventures. Additional participating investors include Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels. ### What key achievements has Cellbyte accomplished? Cellbyte achieved six-figure ARR within weeks of launching and secured major pharmaceutical clients including Bayer. The company operates live in 12 key markets and has reduced drug launch processes from one year to minutes. ### What technology approach does Cellbyte use? Cellbyte utilizes an AI-native architecture that brings clinical, pricing, HTA, regulatory, and internal company data into a unified real-time analytical environment. This approach reduces pharmaceutical launch processes from one year to minutes. ### How can I get started with Cellbyte? Based on the provided information, specific contact details are not available. Cellbyte serves pharmaceutical companies and currently operates live in 12 key markets with major clients like Bayer. ### What are Cellbyte's recent developments? In November 2024, Cellbyte raised $2.75M in seed funding and achieved six-figure ARR within weeks of launching. The company plans to triple its headcount and expand engineering capabilities while continuing weekly market expansion. ## Tags healthtech, analytics, north-america, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*